Clinical Trials Directory

Trials / Terminated

TerminatedNCT00500084

Phase III ALTU-135 CP Safety Trial

An Open-Label Clinical Study Evaluating the Long Term Safety of ALTU-135 in the Treatment of Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis or Pancreatectomy

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
39 (actual)
Sponsor
Anthera Pharmaceuticals · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is an open-label, single-arm clinical study investigating the long-term safety of ALTU-135 treatment in Chronic Pancreatitis (CP) patients with exocrine Pancreatic Insufficiency (PI).

Conditions

Interventions

TypeNameDescription
DRUGLiprotamaseAdministered orally

Timeline

Start date
2007-12-01
Primary completion
2009-03-01
Completion
2009-03-01
First posted
2007-07-12
Last updated
2014-10-24

Locations

11 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00500084. Inclusion in this directory is not an endorsement.